Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma (NeoPancOne)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04472910
Recruitment Status : Recruiting
First Posted : July 16, 2020
Last Update Posted : May 12, 2021
Sponsor:
Collaborator:
Pancreatic Cancer Canada
Information provided by (Responsible Party):
University Health Network, Toronto

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 31, 2025
Estimated Study Completion Date : December 31, 2025